Study of T3D-959 for mild to moderate Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests an oral medicine called T3D-959 for people with mild to moderate Alzheimer's. It aims to see if the drug can help slow memory and thinking decline over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 50 and 90 years old
- A caregiver (family member or friend) who can help you during the study
- Diagnosis of mild to moderate Alzheimer's disease (Stage 4 or 5)
- Must have a positive blood test for a specific Alzheimer's protein (p-tau217)
- Able to swallow pills and generally healthy enough to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This study tests a combination of brain stimulation (TMS) and cognitive training to improve memory and thinking in people with mild Alzheimer's. It may help if you are already on a stable dose of a donepezil-type medication and have a confirmed Alzheimer's diagnosis.
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.